The following is a summary of what could/should happen by midyear with NBIX'S pipeline: 1) Approvals of 2 NDA's resulting in payment of a $100 million milestone-1Q06. 2) Launch of the insomnia drug(s)with partner Pfizer in 2Q06. 3) Four products, MS, Type I Diabetes, Congestive Heart failure, and Endometriosis, completing proof of concept Phase II trials. 1Q and 2Q06. 4) As many as two new products entering Phase I clinical trials 1Q and 2Q06. 5) Phase I data for BPH with NBI56418 in 1Q06. 6) Initiation of two new phase II trials with CRF in Irritable Bowel Syndrome and Depression with partner GSK.
NBIX is worth $50 today just based on Pfizer Indiplon deal and Pending FDA approval. Approval and Launch is worth another $25 in price per share within 6 months. IMO given cash position of NBIX investors get the rest of the pipeline for "FREE". or another way of looking at it $50 plus $10 per share cash = $60 bucks its current trading price. Peak sales for Indiplon via sell-side analyst could be as high as $2B with the Pfizer Marketing Machine driving Sales. With both an IR & MR formulations and different Mg versions Pfizer is going to focus on personalized patient care.